Xeris Biopharma Holdings Inc
NASDAQ:XERS
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Estee Lauder Companies Inc
NYSE:EL
|
Consumer products
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Church & Dwight Co Inc
NYSE:CHD
|
Consumer products
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
American Express Co
NYSE:AXP
|
Financial Services
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Target Corp
NYSE:TGT
|
Retail
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
Mueller Industries Inc
NYSE:MLI
|
Machinery
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
1.47
3.47
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Estee Lauder Companies Inc
NYSE:EL
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Church & Dwight Co Inc
NYSE:CHD
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
American Express Co
NYSE:AXP
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Target Corp
NYSE:TGT
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
Mueller Industries Inc
NYSE:MLI
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one XERS stock under the Base Case scenario is 3.039 USD. Compared to the current market price of 3.115 USD, Xeris Biopharma Holdings Inc is Overvalued by 2%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Xeris Biopharma Holdings Inc
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for XERS cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Xeris Biopharma Holdings Inc
Balance Sheet Decomposition
Xeris Biopharma Holdings Inc
Current Assets | 170.3m |
Cash & Short-Term Investments | 77.6m |
Receivables | 42.4m |
Other Current Assets | 50.3m |
Non-Current Assets | 161.4m |
PP&E | 28.7m |
Intangibles | 127.2m |
Other Non-Current Assets | 5.5m |
Current Liabilities | 75.5m |
Accounts Payable | 5.8m |
Accrued Liabilities | 68.3m |
Other Current Liabilities | 1.4m |
Non-Current Liabilities | 275.5m |
Long-Term Debt | 230.5m |
Other Non-Current Liabilities | 45.1m |
Earnings Waterfall
Xeris Biopharma Holdings Inc
Revenue
|
181.4m
USD
|
Cost of Revenue
|
-29.5m
USD
|
Gross Profit
|
151.9m
USD
|
Operating Expenses
|
-189.1m
USD
|
Operating Income
|
-37.2m
USD
|
Other Expenses
|
-22.4m
USD
|
Net Income
|
-59.6m
USD
|
Free Cash Flow Analysis
Xeris Biopharma Holdings Inc
USD | |
Free Cash Flow | USD |
XERS Profitability Score
Profitability Due Diligence
Xeris Biopharma Holdings Inc's profitability score is 41/100. The higher the profitability score, the more profitable the company is.
Score
Xeris Biopharma Holdings Inc's profitability score is 41/100. The higher the profitability score, the more profitable the company is.
XERS Solvency Score
Solvency Due Diligence
Xeris Biopharma Holdings Inc's solvency score is 36/100. The higher the solvency score, the more solvent the company is.
Score
Xeris Biopharma Holdings Inc's solvency score is 36/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
XERS Price Targets Summary
Xeris Biopharma Holdings Inc
According to Wall Street analysts, the average 1-year price target for XERS is 4.76 USD with a low forecast of 3.03 USD and a high forecast of 6.3 USD.
Dividends
Current shareholder yield for XERS is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Xeris Biopharma Holdings, Inc. is a holding company. The company is headquartered in Chicago, Illinois and currently employs 294 full-time employees. The company went IPO on 2018-06-21. The firm is focused on developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The firm has three commercial products: Gvoke, Keveyis and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome for whom surgery is not an option or has not been curative. Its product candidate also includes Ogluo (EU), Self-Administered Glucagon for prevention, Levothyroxine and XP-9164. The firm uses its non-aqueous formulation technology platforms, XeriSol and XeriJect, to develop and commercialize its products.
Contact
IPO
Employees
Officers
The intrinsic value of one XERS stock under the Base Case scenario is 3.039 USD.
Compared to the current market price of 3.115 USD, Xeris Biopharma Holdings Inc is Overvalued by 2%.